Antileukemic Efficacy of Monomeric Manganese-Based Metal Complex on KG-1A and K562 Cell Lines.

ISRN oncology Pub Date : 2013-10-08 eCollection Date: 2013-01-01 DOI:10.1155/2013/709269

Sandeep Kumar Dash, Sourav Chattopadhyay, Totan Ghosh, Satyajit Tripathy, Sabyasachi Das, Debasis Das, Somenath Roy

{"title":"Antileukemic Efficacy of Monomeric Manganese-Based Metal Complex on KG-1A and K562 Cell Lines.","authors":"Sandeep Kumar Dash, Sourav Chattopadhyay, Totan Ghosh, Satyajit Tripathy, Sabyasachi Das, Debasis Das, Somenath Roy","doi":"10.1155/2013/709269","DOIUrl":null,"url":null,"abstract":"<p><p>Transitional metals and metal compounds have been used in versatile platforms for biomedical applications and therapeutic intervention. Severe side effects of anticancer drugs produce an urgent urge to develop new classes of anticancer agents with great potency as well as selectivity. In this background, recent studies demonstrate that monomeric manganese (MnII) thiocyanate complex (MMTC) holds great promise to exert effective antileukemic effects. MMTC was developed by a simple chemical reaction and characterized by elemental analyses, thermal analyses, and Fourier transform infrared (FTIR) spectroscopy. Anti-leukemic efficacy of the developed MMTC was estimated in KG-1A (AML) and K562 (CML) cell lines. Cell viability study, drug uptake assay, cellular redox balance (GSH and GSSG level), nitric oxide (NO) release level, reactive oxygen species (ROS) formation, alteration of mitochondrial membrane potential (MMP), and DNA fragmentation revealed that MMTC was able to produce significant antiproliferative effects on both cell lines at 25 μ g mL(-1) without showing any toxicological impact on normal lymphocytes. These findings will enlighten the biomedical application of manganese-based metal complexes as anti-leukemic agents. </p>","PeriodicalId":89399,"journal":{"name":"ISRN oncology","volume":"2013 ","pages":"709269"},"PeriodicalIF":0.0000,"publicationDate":"2013-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/709269","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2013/709269","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 22

Abstract

Transitional metals and metal compounds have been used in versatile platforms for biomedical applications and therapeutic intervention. Severe side effects of anticancer drugs produce an urgent urge to develop new classes of anticancer agents with great potency as well as selectivity. In this background, recent studies demonstrate that monomeric manganese (MnII) thiocyanate complex (MMTC) holds great promise to exert effective antileukemic effects. MMTC was developed by a simple chemical reaction and characterized by elemental analyses, thermal analyses, and Fourier transform infrared (FTIR) spectroscopy. Anti-leukemic efficacy of the developed MMTC was estimated in KG-1A (AML) and K562 (CML) cell lines. Cell viability study, drug uptake assay, cellular redox balance (GSH and GSSG level), nitric oxide (NO) release level, reactive oxygen species (ROS) formation, alteration of mitochondrial membrane potential (MMP), and DNA fragmentation revealed that MMTC was able to produce significant antiproliferative effects on both cell lines at 25 μ g mL(-1) without showing any toxicological impact on normal lymphocytes. These findings will enlighten the biomedical application of manganese-based metal complexes as anti-leukemic agents.

Abstract Image

查看原文本刊更多论文

锰基金属单体配合物对KG-1A和K562细胞系的抗白血病作用

过渡金属和金属化合物已用于生物医学应用和治疗干预的多功能平台。抗癌药物的严重副作用促使人们迫切需要开发具有强大效力和选择性的新型抗癌药物。在此背景下，最近的研究表明，单体锰(MnII)硫氰酸盐络合物(MMTC)具有很大的希望发挥有效的抗白血病作用。MMTC由简单的化学反应制备，并通过元素分析、热分析和傅里叶变换红外光谱(FTIR)对其进行了表征。在KG-1A (AML)和K562 (CML)细胞系中估计了开发的MMTC的抗白血病功效。细胞活力研究、药物摄取测定、细胞氧化还原平衡(GSH和GSSG水平)、一氧化氮(NO)释放水平、活性氧(ROS)形成、线粒体膜电位(MMP)改变和DNA断裂显示，MMTC在25 μ g mL(-1)剂量下对两种细胞系均有显著的抗增殖作用，而对正常淋巴细胞无毒理学影响。这些发现将为锰基金属配合物作为抗白血病药物的生物医学应用提供启示。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ISRN oncology

自引率

0.00%

发文量